Abstract | OBJECTIVES: METHODS: Relevant papers were identified via the MEDLINE, PUBMED, and Cochrane Collaboration databases, manual searches of the references of identified papers and review papers on microscopic colitis, as well as searches of abstracts from major gastroenterological meetings. RESULTS: CONCLUSIONS:
Budesonide is effective and well tolerated for inducing and maintaining clinical and histological responses in patients with collagenous colitis, and for inducing clinical and histological responses in patients with lymphocytic colitis. Determining the magnitude of benefit is limited by the small sample sizes of the studies. The evidence for other agents, including bismuth subsalicylate, prednisolone, B. serrata extract, probiotics, and mesalamine with or without cholestyramine is weaker. It is not clear that any of these agents induce or maintain actual remission of collagenous or lymphocytic colitis, as opposed to clinical or histological response.
|
Authors | Nilesh Chande, John K MacDonald, John W D McDonald |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 104
Issue 1
Pg. 235-41; quiz 234, 242
(Jan 2009)
ISSN: 1572-0241 [Electronic] United States |
PMID | 19098875
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Salicylates
- Cholestyramine Resin
- Mesalamine
- Budesonide
- Bismuth Salicylate
|
Topics |
- Anti-Inflammatory Agents
(therapeutic use)
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Budesonide
(therapeutic use)
- Cholestyramine Resin
- Colitis, Microscopic
(drug therapy)
- Humans
- Mesalamine
(therapeutic use)
- Probiotics
(therapeutic use)
- Randomized Controlled Trials as Topic
- Salicylates
(therapeutic use)
|